August 9, 2013
A newbie in the Japanese diabetes market, AstraZeneca K.K. (AZ) has kicked off its promotion for the glucagon-like peptide-1 (GLP-1) receptor agonist exenatideb, aiming to dispel the overemphasized image of GLP-1 preparations for reducing weight. AZ took over the rights...read more